Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OPC-34712: Phase II data

A double-blind Phase II trial in 429 adult MDD patients who exhibited an inadequate response to 1-3 antidepressants showed that daily 1.5 mg OPC-34712 as an adjunct

Read the full 279 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE